Compound or practice · Nutrition

Akkermansia muciniphila

A next-generation gut bacterium linked to metabolic health — one promising human trial, a lot still unknown.

Overall grade
Grade C
Last revised
1
graded outcome
0
references listed

A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.

1 at grade C — 1 graded row

What is known

Each outcome with its grade (how strong the evidence is, A to D), the size of the effect where the entry records one, and how often studies agree.

  • Insulin sensitivity / metabolic markersEvidence grade C

    One key trial

    Smalllow

What is uncertain

Read off the same rows as above. Nothing here is added that the entry does not itself record.

  • Thin evidence: Insulin sensitivity / metabolic markers (grade C).

The evidence in words

What it is

Akkermansia muciniphila is a mucin-degrading gut bacterium whose abundance correlates with leaner, more metabolically healthy people; now sold as a probiotic.

How it works

It strengthens the gut mucus barrier and signals to improve insulin sensitivity and reduce metabolic inflammation.

What the evidence shows

A landmark proof-of-concept trial found pasteurized Akkermansia improved insulin sensitivity and some metabolic markers in overweight adults — notably, the pasteurized form outperformed live. It's early: one main human trial, and long-term data are lacking.

Safety & interactions

Well tolerated in the trial; long-term safety of a novel single-strain probiotic is not established.

Bottom line

A genuinely exciting 'next-gen' probiotic with one supportive metabolic trial — worth watching, not yet a proven staple. The pasteurized form is the studied one.

Entries that share this one's tags or conditions.

Sources

This entry lists no references of its own.

Last revised . A grade is this entry's reading of the evidence, not medical advice.